Tri-Heal Blend (TB-500 + BPC-157 + KPV)
Tri-Heal is a three-peptide recovery blend combining TB-500 (thymosin β4 — systemic actin regulation and cell migration), BPC-157 (cytoprotection, angiogenesis, gut/tendon repair), and KPV (α-MSH C-terminal — anti-inflammatory, NF-κB inhibition). Addresses tissue repair from three complementary angles in a single vial.
⚡ QUICKSTART HIGHLIGHTS
Dosing & Reconstitution Guide
| Vial | BAC Water | Total Conc. | TB-500 Conc. | BPC-157 Conc. | KPV Conc. |
|---|---|---|---|---|---|
| 45 mg blend | 3.0 mL | 15 mg/mL | 8.33 mg/mL | 3.33 mg/mL | 3.33 mg/mL |
Dosing Protocol
| Phase | Daily Dose | Units | Volume | Per-Component Dose |
|---|---|---|---|---|
| Weeks 1–2 (loading) | 1,500 mcg total | 10 units | 0.10 mL | ~833 mcg TB-500 / ~333 mcg BPC-157 / ~333 mcg KPV |
| Weeks 3–4 (loading) | 2,250 mcg total | 15 units | 0.15 mL | ~1.25 mg TB-500 / ~500 mcg BPC-157 / ~500 mcg KPV |
| Weeks 5–8 (maintenance) | 1,500 mcg total | 10 units | 0.10 mL | Standard maintenance |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the blend vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within the window specified above.
How This Works
Tri-Heal stacks three complementary tissue repair mechanisms. TB-500 (Thymosin β4 peptide) — synthetic fragment of the 43-amino acid thymosin β4 — promotes actin polymerization and cell migration to wound sites, reducing inflammation via NF-κB downregulation and stimulating angiogenesis and re-epithelialization. Its systemic distribution makes it effective for body-wide healing contexts.
BPC-157 (Body Protection Compound 157) acts cytoprotectively: it upregulates VEGFR2 (angiogenesis at injury), promotes fibroblast and tendon-cell outgrowth, stabilizes the nitric-oxide system, and provides gut mucosal protection. BPC-157 and TB-500 have complementary cellular targets — together they cover broader aspects of the repair cascade than either alone.
KPV (Lys-Pro-Val — the C-terminal tripeptide of α-MSH) blocks NF-κB nuclear translocation, reducing TNF-α, IL-6, and IL-1β. Its direct anti-inflammatory contribution reduces the inflammatory microenvironment that delays healing, making the combined formulation particularly useful for chronic inflammatory conditions alongside acute repair.
Potential Benefits & Side Effects
Potential Benefits
- Triple mechanism: cell migration (TB-500) + angiogenesis/cytoprotection (BPC-157) + NF-κB inhibition (KPV).
- Broader repair coverage than Wolverine (BPC+TB-500) due to KPV anti-inflammatory addition.
- KPV particularly useful for gut inflammation, IBD, and systemic inflammatory conditions.
- Convenient single vial vs three separate injections.
- TB-500's systemic distribution ensures body-wide healing support.
- BPC-157 covers gut, tendon, ligament, neural, and vascular repair models.
Side Effect Profile
- Generally well-tolerated — all three components have favorable safety profiles.
- Injection-site reactions.
- WADA prohibited (BPC-157 and TB-500 components).
- No established long-term safety data for the combination.
- Theoretical concern: sustained angiogenesis with occult malignancy.
- KPV component: excellent safety — naturally occurring α-MSH fragment.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | −20°C, up to 24 months |
| Reconstituted | 2–8°C | Up to 14 days |